New York, NY -- (SBWIRE) -- 02/01/2014 -- To receive alerts before the crowd, please take 7 seconds to sign up for our Premium SMS Alerts. Grab your cell phone and text the word "PICKS" to "555888”.
StockMarketIntel.com issues a special report on the following stocks: Keryx Biopharmaceuticals (NASDAQ:KERX), Quest Diagnostics Inc (NYSE:DGX), Generex Biotechnology Corporation (OTCMKTS:GNBT), Idera Pharmaceuticals Inc (NASDAQ:IDRA)
Keryx Biopharmaceuticals (NASDAQ:KERX) declined -2.72%, trading on 4.18 million shares, to end the trade at $15.38. The stock changed hands in a range of $15.17 to $15.67, bringing its market capitalization to about $1.37 billion. If we look at its trading history of the past 52 weeks, the share price suffered a low of $6.33 and was moved to the maximum level of $16.21. Keryx Biopharmaceuticals, Inc. (Keryx) is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and renal disease. The Company is developing KRX-0401, an oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, and also affects a number of other key signal transduction pathways, including the Jun N-terminal kinases pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and survival. KRX-0401 is in Phase III clinical development for both refractory advanced colorectal cancer and relapsed / refractory multiple myeloma, and in Phase I and Phase II clinical development for other tumor types.
Is it the Right to Grab KERX after the Recent Slump? Get Free Trend Analysis Here
Quest Diagnostics Inc (NYSE:DGX) added 0.23%, to complete the trading session at $52.50, with a total volume of 3.88 million shares. The stock, on average, trades on a volume of 2.54 million shares. It floated in a range of $51.92 to $52.86 during the last trading session, with a beta value of 0.65. Its market capitalization now moved to about $7.63 billion. In the past 52 weeks, the share price has not declined below $51.80 and above $64.10. Quest Diagnostics Incorporated (Quest Diagnostics), is a provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions. Quest Diagnostics offers United States patients and physicians the access to diagnostic testing services through its nationwide network of laboratories and Company-owned patient service centers.
What was the Moving Force behind DGX on Bullish Run? Read This Research Report
Generex Biotechnology Corporation (OTCMKTS:GNBT) recorded a gain of 0.47% and was in a range of $0.04-$0.04 before closing at $0.0424. The stock completed the day with a total volume of 3.84 million shares, versus an average volume of 8.64 million shares. The share price hit its 52-week low of $0.02 and $0.07 was the best price. Generex Biotechnology Corporation is a Canada-based Company, which develops drug delivery systems and technologies for the treatment of diabetes. The Company has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity.
For How Long GNBT will fight for Profitability? Read This Trend Analysis report
Idera Pharmaceuticals Inc (NASDAQ:IDRA) added 12.62% yesterday, bringing its market capitalization around $216.81 million. The share price, after opening at $4.05, made a high of $4.73 and hovered above $3.90 to end the day at $4.64. The total number of shares that changed hands during the session was 3.73 million shares, as compared to average trading volume of 2.70 million shares. Idera Pharmaceuticals, Inc. is a clinical-stage biotechnology company engaged in the discovery and development of novel synthetic deoxyribonucleic acid (DNA) - and ribonucleic acid (RNA) - based drug candidates. The Company is developing drug candidates that are designed to modulate immune responses mediated through Toll-like Receptors (TLRs).
For How Long IDRA Gloss will Attract Investors? Find out via this report
To receive alerts before the crowd, please take 7 seconds to sign up for our Premium SMS Alerts. Grab your cell phone and text the word "PICKS" to "555888”.
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list.
Neither StockMarketIntel.com, nor its employees and affiliates are registered as investment advisors or broker/dealers in any jurisdiction whatsoever. Through use of this website viewing or using you agree to hold StockMarketIntel.com, its operators, owners, employees, and affiliates harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Readers should always do their own due diligence and consult a financial professional. StockMarketIntel.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockMarketIntel.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled company. Any opinions expressed on this website are statements of judgment as of the date of publication and are subject to change without further notice, and may not necessarily be reprinted in future publications or elsewhere.
Read Full disclaimer at: http://stockmarketintel.com/Disclaimer.htm
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)